Miquel Vila Bover I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR) Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca Email Miquel Vila Bover Email Instituciones de las que forman parte Jefe de grupo Enfermedades Neurodegenerativas Vall Hebron Institut de Recerca I am an ICREA Professor and I lead the Research Group on Neurodegenerative Diseases at the Vall d'Hebron Research Institute (VHIR)
I have a degree in Medicine and Surgery from the University of Barcelona (1993) and a PhD in Neuroscience from the University of Paris 6 (1998). My doctoral work carried out in the laboratory of experimental neurology at the Salpetriere Hospital in Paris (1993-98) contributed to establishing the subthalamic nucleus as the main therapeutic target for the surgical treatment of Parkinson's disease with deep brain stimulation. From 1998 to 2005 I worked at the Movement Disorders Unit of Columbia University in New York (USA), initially as a postdoctoral researcher and from 2001 as an Assistant Professor of Neurology, focusing on the study of the mechanisms of neuronal death in Parkinson's disease to identify new therapeutic targets for this currently incurable neurodegenerative disorder. In 2006 I moved to Barcelona as a Professor at ICREA (Catalan Institute of Research and Advanced Studies) to create and lead a new research group in neurodegenerative diseases at the Vall d'Hebron Research Institute (VHIR). Our group is now part of the Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED) and the Aligning Science Across Parkinson's Collaborative Research Network (ASAP-CRN). I am also an Associate Professor at the Autonomous University of Barcelona, Principal Investigator at CIBERNED, Coordinating Lead PI at ASAP-CRN and member of the Steering Committees of the World Parkinson Coalition and the Basic Science Special Interest Group of the International Parkinson and Movement Disorder Society.
Proyectos Targeting a novel transcriptional pathway to reduce á-synuclein expression IP: Miquel Vila Bover Colaboradores: - Entidad financiadora: Michael J. Fox Foundation Financiación: 31728 Referencia: TARGET,ADV_MJFF2016 M.VILA Duración: 21/12/2016 - 20/06/2018 Estudio del rol patogénico de la disfunción autofágica en la enfermedad de Parkinson asociada a mutaciones en GBA. Desarrollo de nuevos fármacos moduladores de la autofagia como nueva estrategia terapéutica en las enfermedades neurodegenerativas. IP: Miquel Vila Bover Colaboradores: Marta Martínez Vicente, Laia Perez Lasarte Entidad financiadora: Instituto de Salud Carlos III Financiación: 101250 Referencia: CPII15/00007 Duración: 01/01/2016 - 31/12/2018 Apoptosi i Neurodegeneració (GRC) IP: - Colaboradores: Marta Martínez Vicente, Miquel Vila Bover, Joaquin Lopez Soriano, Mercè Boada Rovira, Jordi Bove Badell, Thais Cuadros Arasa Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca Financiación: 30000 Referencia: 2014 SGR 1609 Duración: 01/01/2014 - 31/12/2016 Generation of humanized mouse models to study the role of neuromelanin in Parkinson disease IP: Miquel Vila Bover Colaboradores: - Entidad financiadora: Parkinson's UK Financiación: 48053.2 Referencia: MOUSEMOD_PARKINSONUK2015 Duración: 01/01/2015 - 31/12/2015 Paginación Primera página « Página anterior ‹ … Página 4 Página 5 Página actual 6 Página 7 Página 8 … Siguiente página › Última página »